Arcus Biosciences, Inc. (RCUS) Stock
Fundamentals
Source: third-party data provider, as of October 13, 2026
Compare with RCUS
Recent news

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.10
- MACD 12/26/9
- -0.87
- EMA 9 of MACD
- -0.89
- MACD histogram
- 0.02
- SMA 50
- $27.39
- Price below SMA 50
- EMA 50
- $26.46
- Price below EMA 50
- SMA 200
- $24.83
- Price below SMA 200
- EMA 200
- $24.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences Q2 Earnings Call Highlights
RCUS

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
RCUS

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Arcus Biosciences, Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO | 1960 |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President | 1958 |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO | 1973 |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer | — |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Alexander Azoy CPA | Chief Accounting Officer | 1976 |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer | 1969 |
| Pia Eaves | Vice President of Investor Relations & Strategy | — |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary | 1979 |
| Holli Kolkey | Vice President of Corporate Communications | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 13, 2026
Technical indicators
- RSI 14
- 40.10
- MACD 12/26/9
- -0.87
- EMA 9 of MACD
- -0.89
- MACD histogram
- 0.02
- SMA 50
- $27.39
- Price below SMA 50
- EMA 50
- $26.46
- Price below EMA 50
- SMA 200
- $24.83
- Price below SMA 200
- EMA 200
- $24.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $38.50
- High
- $45.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.9 | +28.4 | -6.2 | |||||||||
| 2022 | -26.4 | +18.2 | -16.0 | -24.3 | -25.2 | +31.7 | +0.3 | -3.2 | +1.7 | -2.7 | +41.1 | -40.0 |
| 2023 | +7.1 | -18.6 | +4.7 | -2.1 | +11.4 | +0.0 | -2.6 | +5.1 | -15.3 | -9.1 | -4.8 | +18.9 |
| 2024 | -23.1 | +20.7 | -1.2 | -17.6 | -2.8 | -3.9 | +7.3 | +9.0 | -7.7 | -0.8 | -0.4 | -6.6 |
| 2025 | -14.7 | -17.5 | -25.2 | +13.5 | +3.6 | -11.7 | +9.2 | +15.6 | +25.8 | +46.3 | +28.3 | -8.7 |
| 2026 | -9.7 | -6.0 | -9.8 | +16.8 | -1.3 | +20.1 | -2.5 | +6.0 | -13.1 | -3.5 |



